UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 19, 2018

 

 

 

CELGENE CORPORATION

(Exact name of registrant as specified in its charter)

 

 

 

         
Delaware   001-34912   22-2711928

(State or other jurisdiction

of incorporation)

 

  

(Commission

File Number)

 

  

(IRS Employer

Identification No.)

 

     

86 Morris Avenue, Summit,

New Jersey

   07901
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (908) 673-9000

 

(Former name or former address, if changed since last report.)

 

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

ITEM 8.01OTHER EVENTS

 

On June 19, 2018, Celgene Corporation announced that Jonathan Biller will succeed Gerald F. Masoudi as Executive Vice President and General Counsel effective July 3, 2018. Mr. Masoudi is leaving Celgene to return to Washington, D.C. with his family and assume the role of Chief Legal Officer with a private company outside of the biopharmaceutical industry.

 

Attached hereto and incorporated by reference as Exhibit 99.1 is the Press Release announcement.

 

ITEM 9.01FINANCIAL STATEMENTS AND EXHIBITS

 

Exhibit 99.1 – Press Release dated June 19, 2018

 

2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

       
  CELGENE CORPORATION
       
Date: June 19, 2018 By:  

/s/ Peter N. Kellogg

      Peter N. Kellogg
      Executive Vice President and Chief Financial Officer
      (Principal Financial and Accounting Officer)

 

3